Drugs, At What Cost?
January 19, 2014 - By: Rita Peters BioPharm International Generics, market dynamics, and global demand are changing drug spending patterns.


The underlying question for any

2014 Manufacturing Trends and Outlook
January 19, 2014 - By: Rita Peters BioPharm International Single-use systems and other technologies drive process efficiencies, but there is room for improvement.


Determining Criticality-Process Parameters and Quality Attributes


January 11, 2014 - By: Mark Mitchell BioPharm International A practical roadmap in three parts that applies scientific knowledge, risk analysis, experimental data, and process monitoring throughout the three phase

Implementing QbD in Sterile Manufacturing
December 31, 2013 - By: Susan Haigney, BioPharm International To gain perspective on the implementation of quality by design (QbD) in sterile manufacturing, BioPharm International spoke with Wolfgang Weikmann, vice-

Biotechnology Innovation and Growth in Israel
December 31, 2013 - By: Jill E. Sackman, Michael Kuchenreuther BioPharm International Israel's diverse population, high-quality healthcare system, and resilience to global financial stress make it a strong partner for R&D, clinical research, and

Climate Change in Outsourcing
December 31, 2013 - By: Jim Miller BioPharm International

As 2013 draws to a close, the bio/pharmaceutical industry continues to be reshaped by changes in the business climate. Financial, political, and scientific deve

Quality by design for biotechnology products—part 1
December 29, 2013 - BioPharm International

A PhRMA Working Group's advice on applying QbD to biotech.

By Taruna Arora, Roger Greene, Jennifer Mercer, Paul Tsang, Meg Casais, Stuart Fe

Comparing Protein A Resins for Monoclonal Antibody Purification
December 16, 2013 - By: Shohei Kobayashi, Yasufumi Ueda BioPharm International A prototype Protein A resin is evaluated for purification performance, reusability, and cost performance.


With greater

ReadyToProcess WAVE 25 Bioreactor System
December 9, 2013 - Cytiva

The single-use ReadyToProcess WAVE 25 bioreactor system is a reliable and intuitive cell culture device for working volumes up to 25 L.

The system is

Bioprocessing Advances in Vaccine Manufacture
December 6, 2013 - Eric S. Langer, Ronald A. Rader BioPharm International

Advances in techniques and single-use systems are revolutionizing vaccine manufacturing.

The vaccine ind

Previous PageNext Page